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Abstract: Alzheimer’s disease (AD) is mainly a late-onset neurodegenerative disorder. 
Substantial efforts have been made to solve the complex genetic architecture of AD as a means 
to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have 
been developed. As therapeutics are likely to be most effective in the early stages of disease 
(ie, before the onset of symptoms), a recent focus of AD research has been the identification 
of protective factors that prevent disease. One example is the discovery of a rare variant in the 
3′-UTR of RAB10 that is protective for AD. Here, we review the possible genetic, molecular, 
and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10.
Keywords: Alzheimer’s disease, RAB10, retromer, APP, resilience, GTPase
Alzheimer’s disease: overview
Alzheimer’s disease (AD) is mainly a late-onset neurodegenerative disease defined 
clinically by progressive memory decline.1 AD currently affects nearly 50 million 
people worldwide, and this number is expected to rapidly increase as the population 
ages (http://www.alz.co.uk/). Neuropathologically, AD is characterized by neuronal 
loss and the accumulation of amyloid plaques and neurofibrillary tangles in the brain, 
much of which occurs many years before the onset of clinical symptoms.2 While 
clinical diagnosis of AD is challenging because it is dependent primarily on observa-
tions of family members and caregivers, changes in protein analytes in plasma and 
cerebrospinal fluid (CSF) and brain imaging, although not widely used in clinical 
practice, may facilitate AD diagnosis.2 AD can broadly be defined either as early-onset, 
occurring prior to age 65, or the much more common late-onset, occurring after age 
65 (96.5% of total cases).
Genetic architecture of AD
The genetics of early-onset AD (EOAD) are relatively well understood. Autosomal 
dominant mutations occurring in APP, PSEN1, or PSEN2 give rise to a subset of EOAD 
cases. More than 200 pathogenic mutations have been reported worldwide (http://
www.molgen.ua.ac.be/admutations/).3 Clinically, EOAD mutation carriers exhibit 
disease onset prior to 65 years of age.4 Neuropathologically, EOAD and late-onset AD 
(LOAD) are indistinguishable.5 Unfortunately, the genetics of LOAD is more complex.
Among individuals with LOAD, there is strong evidence for genetic heritability of 
disease.6–10 The single largest genetic risk factor for LOAD is APOE.11 APOE plays 
critical roles in cholesterol transport, neuroplasticity, and inflammation.12 APOE regu-
lates Aβ metabolism directly through binding and clearance of Aβ13 and indirectly via 
the LRP1 receptor.14 Moreover, APOE influences tau-mediated neurodegeneration.15 
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Two different APOE alleles, ε4 and ε2, affect risk for AD. 
Risk for developing AD is 3-fold higher in individuals carry-
ing one copy of the ε4 allele and 12-fold higher in individu-
als carrying 2 copies of APOE ε4.16 Conversely, APOE ε2 
confers resilience to AD, while the ε3 allele is considered 
neutral risk.16
Genetic variants that influence risk for AD can be broadly 
classified into two groups: common and rare. The majority of 
common variants (minor allele frequency [MAF] 5%) were 
identified using genome-wide association studies (GWAS).17 
With the exception of variants in APOE, all other common 
variants have small effect sizes on AD risk (ORs =1.08–1.22, 
0.73–0.94).17 While GWAS variants provide insights into dis-
ease processes, none of the common risk variants for AD that 
have been identified by GWAS have clear functional effects 
and efforts to identify functional variants in the regions of 
GWAS variants have largely been unsuccessful.
The advent of next-generation sequencing has enabled 
the sequencing of whole exomes and genomes, resulting in 
progressively larger AD datasets and providing insights into 
the contribution of low-frequency (MAF 1%–5%) and rare 
variants (MAF 1%) to the genetic architecture of AD. Using 
a variety of study designs, multiple rare variants have been 
identified that affect risk for AD.18–22 Rare variants typically 
have much larger effect sizes on disease risk than common 
variants identified by GWAS. Rare variants are also more 
likely to occur in coding or regulatory regions and, thus, are 
more likely to be functional. Thus, rare variants represent 
effective therapeutic targets.
Finally, alternative study designs can provide additional 
insights into the genetics of AD. For example, the use of quanti-
tative endophenotypes (eg, CSF levels of protein analytes such 
as Aβ and tau;23–25 mitochondrial copy number;26 metabolic 
efficiency;27,28 measurements of progressive brain atrophy;29 
among others) and the analysis of mitochondrial genomic 
variation30 have expanded our understanding of the genetic 
architecture underlying disease onset and disease course.
Using the genetics of AD to identify 
therapeutic targets
Genes and pathways that regulate AD pathogenesis may 
represent viable targets for treating disease. For example, 
therapies targeting the removal of Aβ or inhibition of Aβ 
production are currently in clinical trials. These strategies 
are based on our understanding of the mechanisms by which 
rare mutations in APP, PSEN1, and PSEN2 drive AD patho-
genesis in EOAD and focus on inhibition of the deposition 
of Aβ in the brain. Similarly, targeting APOE function has 
been investigated for its therapeutic capacity.31–33 AD risk 
genes implicated in immune function, endocytosis, and lipid 
biology represent novel avenues of therapeutic development. 
Unfortunately, to date, more than 90% of all clinical trials 
have failed. Given the expected increase in disease inci-
dence, developing effective therapeutics is imperative. For 
the remainder of this review, we discuss the potential role 
of RAB10 as a therapeutic target.
Protective factors in AD: RAB10
Common and rare variants have been identified that reduce 
the risk for AD.3 Those with the strongest protective effect 
include APOE ε2 and APP-A673T.34,35 Thus, genes and 
pathways involved in increasing AD risk may also confer 
resilience to disease. To identify additional genetic variants 
that confer resilience to AD, there is a need to develop novel 
study designs that focus on those individuals carrying pro-
tective factors for AD. In one such case, family pedigrees 
were identified with a statistical excess of AD mortality 
(ie, families with a higher number of AD deaths than expected 
relative to similarly sized pedigrees; termed high-risk pedi-
grees). Within these high-risk pedigrees, elderly individuals 
with genetic risk for AD (ie, APOE ε4 carriers) but who had 
escaped AD were evaluated using whole-genome sequenc-
ing. Ridge et al identified a rare variant (rs142787485) in the 
3′-UTR of RAB10 that confers resilience to AD.10 In a cell 
model of APP metabolism, silencing of Rab10 expression 
leads to a significant decrease in Aβ42 and the Aβ42/40 ratio, 
consistent with prior reports.10,36 Interestingly, independent 
of the RAB10 SNP, individuals with a neuropathologic diag-
nosis of AD exhibited significantly higher levels of RAB10 
compared to neuropathology-free controls.10 Thus, genetic 
and molecular evidences support a role for RAB10 in AD 
pathogenesis.
RAB10 in AD pathology
RAB10 is expressed in all cell types in the brain.37 RAB10 
is activated by phosphorylation at Thr73, which is mediated 
by LRRK2, a protein kinase associated with Parkinson’s 
disease.38,39 This phosphorylation event may represent a 
pathologic feature in the brains of AD patients.38 pRAB10-
Thr73 was observed to colocalize with neurofibrillary tangles 
in AD brains as well as with granulovascular degeneration, 
neuropil threads, and dystrophic neurons.38 Double immu-
nofluorescence staining of these structures further revealed 
positive staining for phosphorylated tau. However, this 
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RAB10 as a therapeutic target in Alzheimer’s disease
not complete, with some instances showing neuropil threads 
or dystrophic neurons containing only phosphorylated tau or 
only pRAB10-Thr73. Interestingly, dystrophic neurons near 
amyloid plaques stained positive for pRAB10-Thr73, while 
the amyloid plaques themselves were negative for pRAB10.38 
Total RAB10 staining, however, did not differ between AD 
and control brains. Thus, while pRAB10-Thr73 is associated 
with AD pathology, it remains unclear whether this represents 
excess activation or aberrant function of RAB10.
RAB10: function in development
RAB10 is a member of the RAB family of small GTPases, 
which are key regulators of vesicular trafficking. RAB 
proteins are cyclically controlled, requiring a GDP–GTP 
exchange that is facilitated by RAB guanine nucleotide 
exchange factors.40 However, unlike most of the other RAB 
proteins, which have relatively specific roles within intracel-
lular transport, RAB10 is relatively unique because it carries 
out a wide variety of functions and has multiple subcellular 
localizations.41
Rab10 plays essential functional roles in development: 
mice are embryonic lethal when both alleles are deleted.42 
In addition, RAB10 plays a role in maintenance and regula-
tion of endoplasmic reticulum (ER) morphology.43–45 When 
RAB10 is mutated or constitutively inactive (eg, GDP-
locked), the ER contains more cisternae, suggesting that 
RAB10 plays a critical role in maintaining and/or generating 
tubule extension and fusion in the ER.43 RAB10 function has 
also been linked to neuronal morphology and polarization, 
playing a critical role in axonal development and dendrite 
arborization.46,47 During neuronal development, RAB10 
associates with plasmalemmal precursor vesicles, which 
are linked to kinesin 1 via c-Jun N-terminal protein kinase-
interacting protein 1.48 Together this complex mediates 
anterograde transport of RAB10-positive vesicles to axonal 
tips, promoting axonal growth.48 Thus, RAB10 function is 
critical for proper neuronal function.
A role for RAB10 and APP in the 
retromer pathway
RAB10 has been linked to many roles involved in intra-
cellular transport (Figure 1), including but not limited to 
a role in endocytic recycling. In Caenorhabditis elegans, 
RAB10 is required for α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid-type glutamate receptor recycling 
in postsynaptic membranes.49 RAB10 is likely functional 
upstream of RME-1/EHD, a protein involved in recycling 
endosome tubulization and endosome function.50–52 RAB10 
is expressed at the interface of early endosomes and recy-
cling endosomes. These structures are morphologically 
defective in rab-10 mutant C. elegans models.50,51 RAB10 is 
required for endosomal recruitment of CNT-1.53 This likely 
contributes to biogenesis and/or maintenance of recycling 
endosome compartments. RAB10 could also play a role in 
promoting the maturation of early endosomes to recycling 
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RAB10 and RAB3A are essential for lysosomal exocytosis 
and plasma membrane repair.54,55 In addition, RAB10 associ-
ates with lipid droplets.56 Complexes of RAB10–EHBP1–
EHD2 promote autophagic engulfment and degradation of 
lipid droplets.57 Thus, these functional roles for RAB10 in 
recycling and degradation make it an interesting candidate 
protein in AD pathogenesis.
RAB10 is involved in transport of proteins from the 
early endosome to the trans-Golgi network (TGN), where it 
may also function in the retromer pathway.58 The retromer 
complex consists of Vps26, Vps35, Vps29, SNX1, SNX2, 
SNX5, and SNX6.59 The retromer complex regulates trans-
port of protein cargo from endosomes to the TGN by the 
retrograde pathway or to the cell surface through the recy-
cling pathway.60
To form the amyloid plaques that define a primary com-
ponent of AD pathology, the transmembrane APP must first 
be processed into Aβ peptides. APP is thought to be retrieved 
from the cell surface and trafficked to the early endosomes 
where it is initially cleaved by β-site APP-cleaving enzyme 1 
(BACE1) to generate a C-terminal fragment (β-CTF).61,62 The 
β-CTF fragments are then trafficked via retromer-dependent 
transport to the TGN, which facilitates further cleavage by 
γ-secretase to produce Aβ40.63 The retromer complex and 
its receptors can transport APP and BACE1 from endosomes 
to the TGN, ultimately regulating production of Aβ.60 The 
retromer complex sorts APP and BACE, either through direct 
or indirect binding to the transmembrane adaptor protein 
SORLA.64 Interestingly, common variants in the gene that 
encodes SORLA have been associated with AD risk.65 Thus, 
genes that are involved in retromer function may influence 
AD pathogenesis and represent promising therapeutic targets.
Retromer complex dysfunction promotes APP accu-
mulation in neurons and Aβ production. In addition, the 
retromer also appears to have a differential effect on Aβ 
isoforms, with evidence that retromer dysfunction alters 
Aβ40 secretion, which results in increasing the Aβ42/40 
ratio.66 In mouse models, reduction of a single component 
within the retromer complex, Vps26, is sufficient to increase 
soluble Aβ and APP.67 Stabilization of the retromer in human-
induced pluripotent stem cell-derived neurons through the 
use of the pharmacologic chaperone R33 has been shown to 
significantly reduce the phosphorylation of Tau in a man-
ner that correlated with, but ultimately independent of, Aβ 
production.68 An RNAi screen of RABs that modify APP 
processing revealed that the silencing of RAB10 reduces 
Aβ without altering sAPPβ levels.36 The LRRK2-RAB10 
signaling pathway also causes an overproduction of Aβ.38
Therapeutic implications for RAB10
Novel genes and pathways that contribute to the pathogenesis 
of AD provide insights into strategies to prevent or treat the 
disease. The amyloid hypothesis, which proposes that the 
accumulation of Aβ triggers the cascade of events that lead 
to AD, has been the focus of AD therapeutic development for 
decades. The development of anti-Aβ therapeutics remains 
the primary approach to treating AD based on our current 
understanding of the earliest features of this disease.69 In 
this review, we emphasize the importance of RAB10 in the 
processing of APP and the production of Aβ. The function 
of RAB10 in intracellular trafficking and evidence that a 
reduction of Rab10 results in a reduction of the Aβ42/40 ratio 
makes inhibition of RAB10 a potential therapeutic avenue.
There are several existing strategies for therapeutic inhibi-
tion of a gene product. Potential technologies for targeting 
of RAB10 are small molecules, antibodies, and antisense 
oligodeoxynucleotide technologies. For each of these 
approaches the challenge of delivery across the blood–brain 
barrier (BBB) is a significant one.70 A molecule with high 
lipid solubility and molecular mass 400 Da generally can 
diffuse across the BBB. These criteria limit the classes of 
small molecules that can be considered as potential thera-
peutic molecules for AD. Antibodies do not cross the BBB 
at therapeutic concentrations. Several approaches have 
been developed to deliver antibodies to the brain. Bispecific 
antibodies have been developed that leverage the transfer-
rin receptor to successfully increase BBB penetration.71,72 
In addition, antibody analogs that can cross the BBB are in 
development (Patent #EP3309171). Antisense oligonucle-
otides do not readily cross the BBB.73 However, at present, 
intrathecal bolus injection is an effective method for ensuring 
distribution in neurons and glial cells in the brain.74
Approaches to the development and delivery of small-
molecule therapeutics are mature and the path and pitfalls 
are well established. Small molecules are effective enzyme 
inhibitors, receptor ligands, or allosteric modulators. The 
nature of small-molecule activity can make it difficult to 
find the balance between efficacy and side effects when 
treating humans.70 Despite these challenges, small-molecule 
drug development has seen many successes and 90% of 
existing therapeutics use small molecules. Small GTPases 
similar to RAB10 have been successfully targeted using 
small molecules in the past. One important use is the devel-
opment of molecules to block oncogenic properties of the 
RAS protein to treat cancer.75 Recent discoveries about the 
structure of small GTPases and advances in targeting strate-
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RAB10 as a therapeutic target in Alzheimer’s disease
proteins as therapeutic targets.76 Targeting approaches, 
including interference with nucleotide binding, inactiva-
tion by irreversible covalent modification, inhibition of 
GTPase–GEF interactions, inhibition of GTPase–effector 
interactions, and stabilization of GTPase–protein complexes 
have been successful and are reviewed by Cromm et al.76 
While challenges regarding specificity and crossing the 
BBB remain, these advances create some optimism about 
the use of small molecules to inhibit RAB10 and impact 
AD pathology.
Antibodies function in extra- and intracellular immunity 
to recognize foreign or abnormal agents and target them for 
destruction with very high specificity. The production of 
monoclonal antibodies (mAbs) has resulted in their use for 
the treatment of a wide range of human diseases.71 There are 
currently 60 approved mAbs for human therapy and 50 
in late-stage clinical trials.77
RNase H-dependent antisense oligonucleotides technol-
ogy is a popular method for knockdown in cell culture. It 
offers specific and efficient knockdown and is a powerful 
tool for functional studies of genes with unknown function.78 
Antisense technology has challenges such as site specificity, 
toxicity at high concentrations, and the difficulty of target-
ing specific cell types. However, it is a mature technology 
and antisense oligonucleotides offer a means to manipulate 
specific steps in mRNA processing, for example, splicing.69 
As discussed previously, in vitro reduction of Rab10/RAB10 
expression using shRNA and RNAi has been successful.36 
Expansion of antisense oligodeoxynucleotide from in vitro 
to in vivo represents a promising therapeutic avenue 
given recent successes with spinal muscular atrophy and 
Huntington’s disease.79,80
Conclusion
Here we have outlined the potential role of RAB10 in AD 
pathology and the case for RAB10 inhibition as a therapeu-
tic intervention for AD. While small GTPases like RAB10 
present significant challenges for therapeutic development, 
recent work in small molecules, antibodies, and antisense 
oligonucleotides suggests that success can be achieved.
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